Title |
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
|
---|---|
Published in |
BMC Medicine, August 2012
|
DOI | 10.1186/1741-7015-10-92 |
Pubmed ID | |
Authors |
Bjørn H Ebdrup, Filip K Knop, Pelle L Ishøy, Egill Rostrup, Birgitte Fagerlund, Henrik Lublin, Birte Glenthøj |
Abstract |
Antipsychotic-induced weight gain constitutes a major unresolved clinical problem which may ultimately be associated with reducing life expectancy by 25 years. Overweight is associated with brain deterioration, cognitive decline and poor quality of life, factors which are already compromised in normal weight patients with schizophrenia.Here we outline the current strategies against antipsychotic-induced weight gain, and we describe peripheral and cerebral effects of the gut hormone glucagon-like peptide-1 (GLP-1). Moreover, we account for similarities in brain changes between schizophrenia and overweight patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 43% |
Brazil | 1 | 14% |
Denmark | 1 | 14% |
Unknown | 2 | 29% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 43% |
Scientists | 2 | 29% |
Practitioners (doctors, other healthcare professionals) | 2 | 29% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 2% |
Denmark | 1 | 1% |
Australia | 1 | 1% |
Unknown | 78 | 95% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 13 | 16% |
Researcher | 11 | 13% |
Student > Postgraduate | 10 | 12% |
Student > Master | 10 | 12% |
Student > Bachelor | 8 | 10% |
Other | 14 | 17% |
Unknown | 16 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 29 | 35% |
Psychology | 11 | 13% |
Neuroscience | 5 | 6% |
Agricultural and Biological Sciences | 5 | 6% |
Nursing and Health Professions | 2 | 2% |
Other | 8 | 10% |
Unknown | 22 | 27% |